System Entry • 4/5/2026
Sermorelin vs CJC-1295: GHRH-Analog Research Compared
Both peptides stimulate pituitary GH release via GHRH-class signaling—but their chemistries and half-lives differ. A concise comparison for research buyers.
### Shared biology
Sermorelin and CJC-1295 (with or without DAC) are **growth hormone–releasing hormone (GHRH) analogs**. They amplify the pituitary’s endogenous GH pulse rather than acting as ghrelin-mimetic secretagogues (GHRP class).
### Practical research differences
- **Sermorelin**: shorter GHRH fragment historically used in research and clinical development contexts; kinetics differ from long-acting analogs.
- **CJC-1295 (no DAC)**: engineered for **extended plasma exposure** vs native GHRH(1-44); often discussed alongside GHRP co-administration in research forums—but protocols are not provided here.
### Synergy note
Our article on /blog/cjc-1295-ipamorelin-mechanism covers pairing GHRH-class tools with selective secretagogues.
### RUO
Laboratory research only.
*Both sermorelin and CJC-1295 variants are available from peptide limited for qualified research use.*
Related Compounds
Featured Research Compounds

IGF-1 LR3 (1mg)
IGF-1 LR3 (1mg)
212,50 zł

GHRP-2 (5mg)
GHRP-2 (5mg)
42,50 zł

GHRP-6 (5mg)
GHRP-6 (5mg)
42,50 zł